Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease

Urology

Volumn 66, Issue 1, 2005, Pages 156-160

  Antenor, Jo Ann V ^b   Roehl, Kimberly A ^b   Eggener, Scott E ^b   Kundu, Shilajit D ^b   Han, Misop ^b   Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHI SQUARE TEST; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 22344457189     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.01.008     Document Type: Article

References (16)

1. R.J. Babaian, D.A. Johnston, W. Naccarato The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml relation to biopsy strategy J Urol 165 2001 757 760
2. W.J. Catalona, D.S. Smith, D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
3. M. Han, A.W. Partin, M. Zahurak Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 2003 517 523
4. G.W. Hull, F. Rabbani, F. Abbas Cancer control with radical prostatectomy alone in 1,000 consecutive patients J Urol 167 2002 528 534
5. A.V. D'Amico, M.H. Chen, S.B. Malkowicz Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. or less J Urol 167 2002 2025 2030
6. D.S. Smith, P.A. Humphrey, W.J. Catalona The early detection of prostate carcinoma with prostate specific antigen the Washington University experience Cancer 80 1997 1852 1856
7. W.J. Catalona, D.S. Smith, T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
8. J.I. Epstein, P.C. Walsh, M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
9. M. Ohori, T.M. Wheeler, J.K. Dunn The pathological features and prognosis of prostate cancer detectable with current diagnostic tests J Urol 152 1994 1714 1720
10. F.H. Schroder, I. van der Cruijsen-Koeter, H.J. de Koning Prostate cancer detection at low prostate specific antigen J Urol 163 2000 806 812
11. J.S. Krumholtz, G.F. Carvalhal, C.G. Ramos Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 473
12. B. Shekarriz, J. Upadhyay, F.J. Bianco Jr Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy Prostate 48 2001 136 143
13. A.P. Berger, H. Volgger, H. Rogatsch Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens Prostate 53 2002 241 245
14. M. Aleman, P.I. Karakiewicz, P. Kupelian Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL implications for screening Urology 62 2003 70 74
15. S.J. Freedland, M.K. Terris, G.S. Csathy Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen J Urol 171 2004 2215 2220
16. T.A. Stamey Preoperative serum prostate-specific antigen (PSA) below 10 μg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure Clin Chem 47 2001 631 634